Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
GLP-1 receptor agonists in primary care: readiness, equity, and the risk of a two-tiered obesity treatment landscape
Therapeutic advances in endocrinology and metabolism, 2026;17:20420188261472587
Beyond the Scale: Changes in Pain, Physical Function (WOMAC), and Low-Grade Inflammation Following Semaglutide Treatment in Patients with Knee Osteoarthritis-Results from a Six-Month Real-World Cohort
Journal of clinical medicine, 2026;15(15)
Tirzepatide-Associated Severe Hepatocellular Injury: A Case Report and Diagnostic Considerations
Diagnostics (Basel, Switzerland), 2026;16(15)
Weight Recurrence After Bariatric Surgery: Incretin-Based Therapies and the Evolving Role of Revisional Surgery
Cureus, 2026;18(7):e113460
A Case of Severe Hypercalcemia in a Patient Taking Tirzepatide: Potential Risk Factors
Cureus, 2026;18(7):e113391
Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE)
Diabetes, obesity & metabolism, 2026
A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States
PharmacoEconomics, 2026
Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1
Diabetes, obesity & metabolism, 2026
Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment
Medicine;105(30):e49916
Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis
Diabetes & metabolic syndrome, 2026;20(7):103466
Projected budget impact of pharmacotherapy scenarios for obesity and related conditions in Peru: A national survey analysis of 76,819 participants
Obesity pillars, 2026;19:100308
When Weight Loss Turns Dangerous: A Case Report of Tirzepatide-Induced Ketoacidosis in a Non-diabetic Woman
Cureus, 2026;18(7):e113368
Comparative Cardiovascular Pharmacovigilance of Semaglutide and Tirzepatide: A Food and Drug Administration Adverse Event Reporting System (FAERS) Database Analysis (2022-2026)
Cureus, 2026;18(7):e113371
Glucagon-like Peptide-1 Receptor Agonists and Dual Incretin Therapies Across HFpEF and Cardiovascular Outcomes Trials in Patients with Obesity
Medicina (Kaunas, Lithuania), 2026;62(8)
Therapeutic Potential of Anti-Obesity Drugs in Obesity-Associated Female Reproductive Dysfunction: Translating Mechanistic Evidence into Personalized Clinical Strategies
Medicina (Kaunas, Lithuania), 2026;62(8)
Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis
Schizophrenia research, 2026;297:8-16
Tirzepatide-Induced Weight Loss and Exacerbation of Bipolar Disorder With Clozapine Treatment: A Case Report
Journal of clinical psychopharmacology, 2026
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study
Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2026;46(1):2701996
Case Report: Oral semaglutide-associated depression in a patient with type 2 diabetes mellitus: a dose-dependent recurrence confirmed on rechallenge and managed with vortioxetine-bupropion combination therapy
Frontiers in psychiatry, 2026;17:1893173
Incretin analogues as cardiovascular agents: a state-of-the-art review
Frontiers in endocrinology, 2026;17:1898812